One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Cardiac Biomarkers Market

心臓バイオマーカー市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2027年


[ 英語タイトル ] Global Cardiac Biomarkers Market Research Report: Information by Type (Troponins (T and I), Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), ALT/AST), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis), by Location of Testing (Point of Care, Laboratory Testing), and by Region (Americas, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027


Product Code : Market Research FutureHC00115187
Survey : Market Research Future
Publish On : September, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4450 / Question Form
Enterprise User USD6250 / Question Form
Novartis AG (Switzerland), Quidel Corporation (US), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Danaher Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), and Biomérieux SA (France)

[Report Description]

Global Cardiac Biomarkers Market Research Report—Forecast till 2027

Market Dynamics
The global cardiac biomarkers market is expected to exhibit the highest CAGR of 16.36% during the review period of 2020 to 2027 owing to the largest value of USD 4236.02 Million in 2019. The overall cardiac biomarkers market is moderately isolated with rising competition, thing dispatches, rising aggregate affiliations, and other key decisions that are embraced to achieve useful usefulness. The vendors battle reliant upon cost, quality, optimal availability, and constancy of things promoted. The advancement of key market players is dependent upon financial circumstances, government support, and industry improvement. For example, COVID-19 has accepted a critical part in the addition of pursued cardiac biomarkers.
The cardiac biomarkers are primarily used as a coordinated demonstrative methodology for different cardiovascular illnesses. The key factors that drive the cardiac biomarkers market are the expanding commonness of cardiovascular illnesses and way of life infections, expanding pervasiveness of cardiovascular sicknesses and way of life illnesses, expansion sought after for sickness explicit therapy and exploration in which cardiac biomarkers are utilized, innovative headways in cardiac biomarkers, and great government drives to make mindfulness identified with cardiovascular sicknesses. Nonetheless, an absence of mindfulness among individuals is relied upon to hamper market development.
Segmental Overview
The global Cardiac biomarkers market has been classified into Type, application, and location of testing.
By Type segment the market has been classified into cardiac biomarker type - Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA, and others. By Application segment, the market is divided into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. In terms of the location of the testing, the segment is segmented as point-of-care testing and laboratory testing.
Regional Analysis
Geographically, the global cardiac biomarker market has been classified into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
Americas is likely to dominate the global cardiac biomarker market owing to the increasing demand for cardiac testing, increasing prevalence of CVD rate, and the increasing awareness of cardiac diagnostics solutions. The regional market growth is attributed to the high rate of cardiovascular diseases & diabetes, product launch, and acquisition in this region.
The market in Asia-Pacific is rising at the fastest CAGR owing to modernization, increasing disposable incomes, and rising affordability for advanced cardiac treatments. The regional market growth is driven by the rising prevalence of cardiovascular diseases, COPD, and diabetes.
Major Players
The key market players in the global cardiac biomarkers market include Novartis AG (Switzerland), Quidel Corporation (US), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Danaher Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), and Biomérieux SA (France).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.


TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

2.3 MARKET STRUCTURE 15

2.4 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS 24

4.1 OVERVIEW 24

4.2 DRIVERS 24

4.2.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASE AND LIFESTYLE RELATED DISEASES 24

4.2.2 INCREASE IN DEMAND FOR DISEASE-SPECIFIC TREATMENT & RESEARCH IN WHICH CARDIAC BIOMARKERS ARE USED 25

4.3 RESTRAINTS 26

4.3.1 LACK OF AWARENESS AMONG PEOPLE 26

5 MARKET FACTOR ANALYSIS 27

5.1 VALUE CHAIN ANALYSIS 27

5.1.1 R&D AND DESIGNING 28

5.1.2 MANUFACTURING 28

5.1.3 DISTRIBUTION & SALES 28

5.1.4 POST-SALES MONITORING 28

5.2 PORTER’S FIVE FORCES MODEL 29

5.2.1 BARGAINING POWER OF SUPPLIERS 30

5.2.2 BARGAINING POWER OF BUYERS 30

5.2.3 THREAT OF NEW ENTRANTS 30

5.2.4 THREAT OF SUBSTITUTES 30

5.2.5 INTENSITY OF RIVALRY 30

5.3 COVID-19 IMPACT ANALYSIS 31

6 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE 32

6.1 OVERVIEW 32

6.2 TROPONINS (T AND I) 33

6.3 MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB) 34

6.4 MYOGLOBIN 34

6.5 BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP 35

6.6 ISCHEMIA MODIFIED ALBUMIN (IMA) 35

6.7 ALT/AST 36

6.8 OTHERS 36

7 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION 37

7.1 OVERVIEW 37

7.2 MYOCARDIAL INFARCTION 38

7.3 CONGESTIVE HEART FAILURE 39

7.4 ACUTE CORONARY SYNDROME 39

7.5 ATHEROSCLEROSIS 40

7.6 OTHERS 40

8 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING 41

8.1 OVERVIEW 41

8.2 POINT OF CARE TESTING 42

8.3 LABORATORY TESTING 42

9 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION 43

9.1 OVERVIEW 43

9.2 AMERICAS 45

9.2.1 NORTH AMERICA 47

9.2.1.1 US 49

9.2.1.2 CANADA 51

9.2.2 LATIN AMERICA 52

9.3 EUROPE 53

9.3.1 WESTERN EUROPE 55

9.3.1.1 GERMANY 57

9.3.1.2 UK 58

9.3.1.3 FRANCE 59

9.3.1.4 ITALY 60

9.3.1.5 SPAIN 61

9.3.1.6 REST OF WESTERN EUROPE 62

9.3.2 EASTERN EUROPE 63

9.4 ASIA-PACIFIC 64

9.4.1 CHINA 66

9.4.2 INDIA 67

9.4.3 JAPAN 68

9.4.4 SOUTH KOREA 69

9.4.5 AUSTRALIA 70

9.4.6 REST OF ASIA-PACIFIC 71

9.5 MIDDLE EAST & AFRICA 72

9.5.1 MIDDLE EAST 74

9.5.2 AFRICA 75

10 COMPETITIVE LANDSCAPE 76

10.1 OVERVIEW 76

10.2 MAJOR PLAYERS IN THE GLOBAL CARDIAC BIOMARKERS MARKET 77

11 COMPANY PROFILES 78

11.1 NOVARTIS AG 78

11.1.1 COMPANY OVERVIEW 78

11.1.2 FINANCIAL OVERVIEW 79

11.1.3 PRODUCTS/SERVICES OFFERED 79

11.1.4 KEY DEVELOPMENTS 80

11.1.5 SWOT ANALYSIS 80

11.1.6 KEY STRATEGIES 80

11.2 QUIDEL CORPORATION 81

11.2.1 COMPANY OVERVIEW 81

11.2.2 FINANCIAL OVERVIEW 82

11.2.3 PRODUCTS/SERVICES OFFERED 82

11.2.4 KEY DEVELOPMENTS 82

11.2.5 SWOT ANALYSIS 83

11.2.6 KEY STRATEGIES 83

11.3 ACS BIOMARKER B.V. 84

11.3.1 COMPANY OVERVIEW 84

11.3.2 FINANCIAL OVERVIEW 84

11.3.3 PRODUCTS/SERVICES OFFERED 84

11.3.4 KEY DEVELOPMENTS 84

11.3.5 SWOT ANALYSIS 85

11.3.6 KEY STRATEGIES 85

11.4 RANDOX LABORATORIES LTD 86

11.4.1 COMPANY OVERVIEW 86

11.4.2 FINANCIAL OVERVIEW 86

11.4.3 PRODUCTS/SERVICES OFFERED 86

11.4.4 KEY DEVELOPMENTS 86

11.4.5 SWOT ANALYSIS 87

11.4.6 KEY STRATEGIES 87

11.5 TRIVITRON HEALTHCARE 88

11.5.1 COMPANY OVERVIEW 88

11.5.2 FINANCIAL OVERVIEW 88

11.5.3 PRODUCTS/SERVICES OFFERED 88

11.5.4 KEY DEVELOPMENTS 88

11.5.5 SWOT ANALYSIS 89

11.5.6 KEY STRATEGIES 89

11.6 F. HOFFMAN LA ROCHE LTD 90

11.6.1 COMPANY OVERVIEW 90

11.6.2 FINANCIAL OVERVIEW 91

11.6.3 PRODUCTS/SERVICES OFFERED 92

11.6.4 KEY DEVELOPMENTS 92

11.6.5 SWOT ANALYSIS 92

11.6.6 KEY STRATEGIES 93

11.7 JOHNSON & JOHNSON SERVICES INC. 94

11.7.1 COMPANY OVERVIEW 94

11.7.2 FINANCIAL OVERVIEW 95

11.7.3 PRODUCTS/SERVICES OFFERED 95

11.7.4 KEY DEVELOPMENTS 96

11.7.5 SWOT ANALYSIS 96

11.7.6 KEY STRATEGIES 96

11.8 ABBOTT LABORATORIES 97

11.8.1 COMPANY OVERVIEW 97

11.8.2 FINANCIAL OVERVIEW 98

11.8.3 PRODUCTS/SERVICES OFFERED 98

11.8.4 KEY DEVELOPMENTS 99

11.8.5 SWOT ANALYSIS 99

11.8.6 KEY STRATEGIES 99



11.9 SIEMENS 100

11.9.1 COMPANY OVERVIEW 100

11.9.2 FINANCIAL OVERVIEW 101

11.9.3 PRODUCTS/SERVICES OFFERED 101

11.9.4 KEY DEVELOPMENTS 102

11.9.5 SWOT ANALYSIS 102

11.9.6 KEY STRATEGIES 102

11.10 THERMO FISHER SCIENTIFIC INC. 103

11.10.1 COMPANY OVERVIEW 103

11.10.2 FINANCIAL OVERVIEW 104

11.10.3 PRODUCTS/SERVICES OFFERED 105

11.10.4 KEY DEVELOPMENTS 105

11.10.5 SWOT ANALYSIS 106

11.10.6 KEY STRATEGIES 106

11.11 BIO-RAD LABORATORIES, INC. 107

11.11.1 COMPANY OVERVIEW 107

11.11.2 FINANCIAL OVERVIEW 108

11.11.3 PRODUCTS/SERVICES OFFERED 108

11.11.4 KEY DEVELOPMENTS 108

11.11.5 SWOT ANALYSIS 109

11.11.6 KEY STRATEGIES 109

11.12 DANAHER CORPORATION 110

11.12.1 COMPANY OVERVIEW 110

11.12.2 FINANCIAL OVERVIEW 111

11.12.3 PRODUCTS/SERVICES OFFERED 111

11.12.4 KEY DEVELOPMENTS 112

11.12.5 SWOT ANALYSIS 112

11.12.6 KEY STRATEGIES 112

11.13 BIOMÉRIEUX SA 113

11.13.1 COMPANY OVERVIEW 113

11.13.2 FINANCIAL OVERVIEW 114

11.13.3 PRODUCTS/SERVICES OFFERED 115

11.13.4 KEY DEVELOPMENTS 115

11.13.5 SWOT ANALYSIS 116

11.13.6 KEY STRATEGIES 116



12 APPENDIX 117

12.1 REFERENCES 117

12.2 RELATED REPORTS 117

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

TABLE 3 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 33

TABLE 4 GLOBAL CARDIAC BIOMARKERS MARKET FOR TROPONINS (T AND I), BY REGION, 2017–2027(USD MILLION) 33

TABLE 5 GLOBAL CARDIAC BIOMARKERS MARKET FOR MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY REGION,

2017–2027 (USD MILLION) 34

TABLE 6 GLOBAL CARDIAC BIOMARKERS MARKET FOR MYOGLOBIN, BY REGION, 2017–2027 (USD MILLION) 34

TABLE 7 GLOBAL CARDIAC BIOMARKERS MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY REGION,

2017–2027 (USD MILLION) 35

TABLE 8 GLOBAL CARDIAC BIOMARKERS MARKET FOR ISCHEMIA MODIFIED ALBUMIN (IMA), BY REGION, 2017–2027 (USD MILLION) 35

TABLE 9 GLOBAL CARDIAC BIOMARKERS MARKET FOR ALT/AST, BY REGION, 2017–2027 (USD MILLION) 36

TABLE 10 GLOBAL CARDIAC BIOMARKERS MARKET FOR OTHERS, BY REGION, 2017–2027 (USD MILLION) 36

TABLE 11 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2017–2027 (USD MILLION) 38

TABLE 12 GLOBAL CARDIAC BIOMARKERS MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2017–2027 (USD MILLION) 38

TABLE 13 GLOBAL CARDIAC BIOMARKERS MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2017–2027 (USD MILLION) 39

TABLE 14 GLOBAL CARDIAC BIOMARKERS MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2017–2027 (USD MILLION) 39

TABLE 15 GLOBAL CARDIAC BIOMARKERS MARKET FOR ATHEROSCLEROSIS, BY REGION, 2017–2027(USD MILLION) 40

TABLE 16 GLOBAL CARDIAC BIOMARKERS MARKET FOR OTHERS, BY REGION, 2017–2027 (USD MILLION) 40

TABLE 17 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 41

TABLE 18 GLOBAL CARDIAC BIOMARKERS MARKET FOR POINT OF CARE TESTING, BY REGION, 2017–2027 (USD MILLION) 42

TABLE 19 GLOBAL CARDIAC BIOMARKERS MARKET FOR LABORATORY TESTING, BY REGION, 2017–2027 (USD MILLION) 42

TABLE 20 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION, 2017–2027 (USD MILLION) 44

TABLE 21 AMERICAS CARDIAC BIOMARKERS MARKET, BY REGION, 2017–2027 (USD MILLION) 45

TABLE 22 AMERICAS CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 45

TABLE 23 AMERICAS CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 46

TABLE 24 AMERICAS CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 46

TABLE 25 NORTH AMERICA CARDIAC BIOMARKERS MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 47

TABLE 26 NORTH AMERICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 47

TABLE 27 NORTH AMERICA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 48

TABLE 28 NORTH AMERICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027(USD MILLION) 48

TABLE 29 US CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 49

TABLE 30 US CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 49

TABLE 31 US CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 50

TABLE 32 CANADA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 51

TABLE 33 CANADA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 51

TABLE 34 CANADA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 51

TABLE 35 LATIN AMERICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 52

TABLE 36 LATIN AMERICA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 52

TABLE 37 LATIN AMERICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 52

TABLE 38 EUROPE CARDIAC BIOMARKERS MARKET, BY REGION, 2017–2027 (USD MILLION) 53

TABLE 39 EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 53

TABLE 40 EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 54

TABLE 41 EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 54

TABLE 42 WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 55

TABLE 43 WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 56

TABLE 44 WESTERN EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 56

TABLE 45 WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 56

TABLE 46 GERMANY CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 57

TABLE 47 GERMANY CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 57

TABLE 48 GERMANY CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 57

TABLE 49 UK CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 58

TABLE 50 UK CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 58

TABLE 51 UK CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 58

TABLE 52 FRANCE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 59

TABLE 53 FRANCE CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 59

TABLE 54 FRANCE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 59

TABLE 55 ITALY CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 60

TABLE 56 ITALY CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 60

TABLE 57 ITALY CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 60

TABLE 58 SPAIN CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 61

TABLE 59 SPAIN CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 61

TABLE 60 SPAIN CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 61

TABLE 61 REST OF WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 62

TABLE 62 REST OF WESTERN EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 62

TABLE 63 REST OF WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 62

TABLE 64 EASTERN EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 63

TABLE 65 EASTERN EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 63

TABLE 66 EASTERN EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 63

TABLE 67 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 64

TABLE 68 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 65

TABLE 69 ASIA-PACIFIC CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 65

TABLE 70 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 65

TABLE 71 CHINA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 66

TABLE 72 CHINA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 66

TABLE 73 CHINA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 66

TABLE 74 INDIA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 67

TABLE 75 INDIA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 67

TABLE 76 INDIA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 67

TABLE 77 JAPAN CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 68

TABLE 78 JAPAN CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 68

TABLE 79 JAPAN CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 68

TABLE 80 SOUTH KOREA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 69

TABLE 81 SOUTH KOREA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 69

TABLE 82 SOUTH KOREA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 69

TABLE 83 AUSTRALIA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 70

TABLE 84 AUSTRALIA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 70

TABLE 85 AUSTRALIA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 70

TABLE 86 REST OF ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 71

TABLE 87 REST OF ASIA-PACIFIC CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 71

TABLE 88 REST OF ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 71

TABLE 89 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET, BY REGION, 2017–2027 (USD MILLION) 72

TABLE 90 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 73

TABLE 91 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 73

TABLE 92 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 73

TABLE 93 MIDDLE EAST CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 74

TABLE 94 MIDDLE EAST CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 74

TABLE 95 MIDDLE EAST CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 74

TABLE 96 AFRICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017–2027 (USD MILLION) 75

TABLE 97 AFRICA CARDIAC BIOMARKERS, BY APPLICATION, 2017–2027 (USD MILLION) 75

TABLE 98 AFRICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017–2027 (USD MILLION) 75

TABLE 99 MAJOR PLAYERS IN THE GLOBAL CARDIAC BIOMARKERS MARKET 77

TABLE 100 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 79

TABLE 101 QUIDEL CORPORATION: PRODUCTS/SERVICES OFFERED 82

TABLE 102 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 84

TABLE 103 RANDOX LABORATORIES LTD: PRODUCTS/SERVICES OFFERED 86

TABLE 104 TRIVITRON HEALTHCARE: PRODUCTS/SERVICES OFFERED 88

TABLE 105 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 92

TABLE 106 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED 95

TABLE 107 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 98

TABLE 108 SIEMENS: PRODUCTS/SERVICES OFFERED 101

TABLE 109 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 105

TABLE 110 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 108

TABLE 111 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 111

TABLE 112 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 115

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 GLOBAL CARDIAC BIOMARKERS MARKET STRUCTURE 15

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21

FIGURE 4 MARKET DYNAMICS: CARDIAC BIOMARKER MARKET 24

FIGURE 5 DRIVERS: IMPACT ANALYSIS 25

FIGURE 6 RESTRAINTS: IMPACT ANALYSIS 26

FIGURE 7 VALUE CHAIN: CARDIAC BIOMARKERS MARKET 27

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: CARDIAC BIOMARKERS MARKET 29

FIGURE 9 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE, 2019 & 2027 (USD MILLION) 32

FIGURE 10 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2019 & 2027 (USD MILLION) 37

FIGURE 11 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2019 & 2027 (USD MILLION) 41

FIGURE 12 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION 2019 & 2027 (USD MILLION) 43

FIGURE 13 GLOBAL CARDIAC BIOMARKERS MARKET SHARE, BY REGION 2019 (%) 44

FIGURE 14 AMERICAS CARDIAC BIOMARKERS MARKET SHARE, BY REGION 2019 (%) 45

FIGURE 15 WESTERN EUROPE CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY 2019 (%) 55

FIGURE 16 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY 2019 (%) 64

FIGURE 17 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET SHARE, BY REGION 2019 (%) 72

FIGURE 18 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 79

FIGURE 19 NOVARTIS AG: SWOT ANALYSIS 80

FIGURE 20 QUIDEL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 82

FIGURE 21 QUIDEL CORPORATION: SWOT ANALYSIS 83

FIGURE 22 ACS BIOMARKER B.V.: SWOT ANALYSIS 85

FIGURE 23 RANDOX LABORATORIES LTD: SWOT ANALYSIS 87

FIGURE 24 TRIVITRON HEALTHCARE: SWOT ANALYSIS 89

FIGURE 25 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 91

FIGURE 26 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS 92

FIGURE 27 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT 95

FIGURE 28 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS 96

FIGURE 29 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 98

FIGURE 30 ABBOTT LABORATORIES: SWOT ANALYSIS 99

FIGURE 31 SIEMENS: FINANCIAL OVERVIEW SNAPSHOT 101

FIGURE 32 SIEMENS: SWOT ANALYSIS 102

FIGURE 33 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 104

FIGURE 34 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 106

FIGURE 35 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 108

FIGURE 36 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 109

FIGURE 37 DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 111

FIGURE 38 DANAHER CORPORATION: SWOT ANALYSIS 112

FIGURE 39 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 114

FIGURE 40 BIOMÉRIEUX SA: SWOT ANALYSIS 116

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+